WallStreetZenWallStreetZen

NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for TSHA

Based on 12 analysts offering 12 month price targets for Taysha Gene Therapies Inc.
Min Forecast
$1.50+110.08%
Avg Forecast
$6.21+769.47%
Max Forecast
$13.00+1,720.73%

Should I buy or sell TSHA stock?

Based on 12 analysts offering ratings for Taysha Gene Therapies Inc.
Buy
Strong Buy
5 analysts 41.67%
Buy
4 analysts 33.33%
Hold
3 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TSHA stock forecasts and price targets.

TSHA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Canaccord Genuity
Top 7%
94
Strong BuyMaintains$13.00+1,720.73%2023-02-01
Chardan Capital
Top 20%
81
Strong BuyMaintains$6.00+740.34%2023-02-01
Truist Securities
Bottom 14%
14
Strong BuyMaintains$4.00+460.22%2023-02-01
Cantor Fitzgerald
Top 4%
97
Strong BuyReiterates$13.00+1,720.73%2023-02-01
Jefferies
Bottom 8%
8
HoldDowngrades$1.50+110.08%2023-02-01
JMP Securities
Bottom 7%
7
BuyMaintains$4.00+460.22%2023-02-01
Baird
Bottom 1%
1
BuyMaintains$6.00+740.34%2023-02-01
Needham
Bottom 3%
3
BuyMaintains$6.00+740.34%2023-02-01
Morgan Stanley
Bottom 12%
12
HoldDowngrades$3.00+320.17%2023-01-27
Wells Fargo
Bottom 2%
2
Strong BuyMaintains$10.00+1,300.56%2023-01-04

1 of 2

Forecast return on equity

Is TSHA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is TSHA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

TSHA earnings per share forecast

What is TSHA's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
-$2.65
Avg 2 year Forecast
-$2.62
Avg 3 year Forecast
-$1.52

TSHA revenue forecast

What is TSHA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$7.5M
Avg 2 year Forecast
$60.0M
Avg 3 year Forecast
$111.9M

TSHA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TSHA$0.71$6.21+769.47%Buy
HOOK$0.81$4.50+456.24%Buy
NXTC$1.62$9.00+455.56%Strong Buy
BYSI$1.16$10.77+828.10%Hold
MGTA$0.76$4.33+470.13%Strong Buy
View Top Biotech Stocks

Taysha Gene Therapies Stock Forecast FAQ

Is Taysha Gene Therapies Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: TSHA) stock is to Buy TSHA stock.

Out of 12 analysts, 5 (41.67%) are recommending TSHA as a Strong Buy, 4 (33.33%) are recommending TSHA as a Buy, 3 (25%) are recommending TSHA as a Hold, 0 (0%) are recommending TSHA as a Sell, and 0 (0%) are recommending TSHA as a Strong Sell.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.

What is TSHA's earnings growth forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Taysha Gene Therapies's earnings in 2023 is -$160,677,000.On average, 7 Wall Street analysts forecast TSHA's earnings for 2023 to be -$165,472,045, with the lowest TSHA earnings forecast at -$278,492,573, and the highest TSHA earnings forecast at -$93,038,999. On average, 3 Wall Street analysts forecast TSHA's earnings for 2024 to be -$163,598,776, with the lowest TSHA earnings forecast at -$187,326,843, and the highest TSHA earnings forecast at -$130,504,367.

In 2025, TSHA is forecast to generate -$94,912,267 in earnings, with the lowest earnings forecast at -$98,658,804 and the highest earnings forecast at -$91,165,730.

What is TSHA's revenue growth forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Taysha Gene Therapies's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast TSHA's revenue for 2023 to be $467,692,685, with the lowest TSHA revenue forecast at $404,001,558, and the highest TSHA revenue forecast at $531,383,811. On average, 2 Wall Street analysts forecast TSHA's revenue for 2024 to be $3,744,975,803, with the lowest TSHA revenue forecast at $933,512,101, and the highest TSHA revenue forecast at $6,556,439,505.

In 2025, TSHA is forecast to generate $6,985,730,187 in revenue, with the lowest revenue forecast at $1,448,036,496 and the highest revenue forecast at $12,523,423,877.

What is TSHA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: TSHA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is TSHA's Price Target?

According to 12 Wall Street analysts that have issued a 1 year TSHA price target, the average TSHA price target is $6.21, with the highest TSHA stock price forecast at $13.00 and the lowest TSHA stock price forecast at $1.50.

On average, Wall Street analysts predict that Taysha Gene Therapies's share price could reach $6.21 by Feb 1, 2024. The average Taysha Gene Therapies stock price prediction forecasts a potential upside of 769.47% from the current TSHA share price of $0.71.

What is TSHA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's current Earnings Per Share (EPS) is -$4.12. On average, analysts forecast that TSHA's EPS will be -$2.65 for 2023, with the lowest EPS forecast at -$4.46, and the highest EPS forecast at -$1.49. On average, analysts forecast that TSHA's EPS will be -$2.62 for 2024, with the lowest EPS forecast at -$3.00, and the highest EPS forecast at -$2.09. In 2025, TSHA's EPS is forecast to hit -$1.52 (min: -$1.58, max: -$1.46).

What is TSHA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: TSHA) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.